Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertussis Vaccination Models in Pregnant Women
NCT03909126Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire Sainte-Justine
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of acellular pertussis vaccine in pertussis (4 arms), sponsored by Centre Hospitalier Universitaire Sainte-Justine. Primary endpoints: Proportion of pregnant women vaccinated against pertussis at 11 months, Proportion of pregnant women who consider pertussis as serious risk for infant at 12 months and 2 more. Started Jun 2019; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT03909126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909126.